Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Ibrilatazar |
| Trade Name | |
| Synonyms | ABTL-0812|ABTL0812|ABTL 0812|LP10218|LP 10218|SCLN-0812|2-Hydroxylinoleic Acid |
| Drug Descriptions |
Ibrilatazar is a lipid analog that inhibits mTOR and DHFR, potentially resulting in decreased tumor cell proliferation and increased tumor cell death (Cancer Res April 15, 2012 72:922, PMID: 32397857). |
| DrugClasses | mTOR Inhibitor 51 |
| CAS Registry Number | 57818-44-7 |
| NCIT ID | C117290 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Carboplatin + Ibrilatazar + Paclitaxel | Carboplatin Ibrilatazar Paclitaxel | 0 | 0 |
| Fluorouracil + Ibrilatazar + Irinotecan + Oxaliplatin | Fluorouracil Ibrilatazar Irinotecan Oxaliplatin | 0 | 1 |
| Ibrilatazar | Ibrilatazar | 0 | 0 |